EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
What You Should Know: – A new report from Barnes & Thornburg reveals that healthcare compliance professionals are facing mounting pressure as they navigate a
A South African court ruled the government must disclose contracts signed with pharmaceutical companies for Covid-19 vaccines, a victory for advocates who alleged that authorities
Opioid use during pregnancy is not associated with a substantial increase in the risk of neuropsychiatric disorders such as ADHD in children, finds a large